Evidence map›Paper›PMID 42602331›Full record

ArticleGenes & diseases2026

H2AX phosphorylation driven by the SET-PP2A axis maintains glioma stem cell properties.

Chunhua Han, Na Li, Ananya Banerjee, Linzhou Wang, Yajing Yang, Yaogang Zhong, Sophia Wu, Heather Manring, Nan Zhang, Christian A Showalter and 10 more

Abstract read
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Chunhua HanDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Na LiDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Ananya BanerjeeDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Linzhou WangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Yajing YangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Yaogang ZhongDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Sophia WuDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Heather ManringDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Nan ZhangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Christian A ShowalterDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Karnika SinghDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Zhen-Yue TongDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Xiaomei MengDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Zaid SirhanDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Jaharul HaqueDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Qingfei ZhengDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Monica VenereDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Deliang GuoDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Qi-En WangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Arnab ChakravartiDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma harbors a subpopulation of glioma stem cells (GSCs) that drive tumor relapse and invasion. Although GSC properties are known to be regulated by key transcription factors and chromatin remodeling, the mechanisms governing stemness-associated gene expression and the role of histone proteins in this process remain poorly understood. Here, we revealed that GSCs possessed an increased level of histone variant H2AX and phosphorylated H2AX at Ser 139 (γH2AX). CRISPR-Cas9-mediated deletion of H2AX demonstrated its critical role in maintaining GSC self-renewal, tumorigenicity, and the expression of multiple stemness-associated genes. Reintroduction of wild-type H2AX, but not the phosphorylation-deficient S139A mutant, restored GSC properties in H2AX-knockout cells, underscoring the importance of H2AX phosphorylation. We further identified that the elevated γH2AX levels in GSCs result from suppressed PP2A phosphatase activity, driven by increased expression of the SET oncoprotein. Pharmacological reactivation of PP2A effectively reduced γH2AX levels in GSCs. Collectively, our findings uncover a novel mechanism for GSC maintenance and highlight the SET-PP2A axis as a key regulator of γH2AX levels, offering a potential therapeutic target to disrupt GSC-driven tumor growth.

Indexed as

GlioblastomaGlioma stem cellsH2AXPP2ASETγH2AX

Identifiers

PMID42602331
PMCPMC13474088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.